DBV TECHNOLOGIES SA (DBV.PA) Stock Price & Overview
EPA:DBV • FR0010417345
The current stock price of DBV.PA is 3.77 EUR. Today DBV.PA is up by 0.13%. In the past month the price increased by 3.58%. In the past year, price increased by 363.67%.
DBV.PA Key Statistics
- Market Cap
- 207.193M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.66
- Dividend Yield
- N/A
DBV.PA Stock Performance
DBV.PA Stock Chart
DBV.PA Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to DBV.PA. When comparing the yearly performance of all stocks, DBV.PA is one of the better performing stocks in the market, outperforming 99.52% of all stocks.
DBV.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to DBV.PA. Both the profitability and financial health of DBV.PA have multiple concerns.
DBV.PA Earnings
On October 28, 2025 DBV.PA reported an EPS of -0.24 and a revenue of 2.77M. The company beat EPS expectations (4.95% surprise) and beat revenue expectations (319.32% surprise).
DBV.PA Forecast & Estimates
8 analysts have analysed DBV.PA and the average price target is 5.83 EUR. This implies a price increase of 54.69% is expected in the next year compared to the current price of 3.77.
For the next year, analysts expect an EPS growth of -36.93% and a revenue growth -55.09% for DBV.PA
DBV.PA Groups
Sector & Classification
DBV.PA Financial Highlights
Over the last trailing twelve months DBV.PA reported a non-GAAP Earnings per Share(EPS) of -0.66. The EPS increased by 43.66% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -85.56% | ||
| ROE | -142.22% | ||
| Debt/Equity | 0.08 |
DBV.PA Ownership
DBV.PA Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 25.41 | 38.504B | ||
| 1AE | ARGENX SE | 25.73 | 38.43B | ||
| 22UA | BIONTECH SE-ADR | N/A | 20.836B | ||
| 2X1 | ABIVAX SA | N/A | 7.449B | ||
| ABVX | ABIVAX SA | N/A | 7.433B | ||
| GXE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG | GALAPAGOS NV | N/A | 1.856B | ||
| NANO | NANOBIOTIX | N/A | 1.386B | ||
| 6IV | INVENTIVA SA | N/A | 1.094B | ||
| IVA | INVENTIVA SA | N/A | 1.071B | ||
| PHIL | PHILOGEN SPA | 17.21 | 628.66M | ||
| GNFT | GENFIT | 847.06 | 426.025M | ||
| XUP | GENFIT | N/A | 425.025M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Paris Exchange | Find stocks with similar TA and Setup ratings on the EuroNext exchanges | Find stocks with similar Fundamental rating on the EuroNext exchanges | Find the competitors with the best technical ratings on the EuroNext exchanges | Find the competitors with the best fundamentals on the EuroNext exchanges | Find the competitors with the best valuation on the EuroNext exchanges | Find the competitors with the best dividend on the EuroNext exchanges | Find the competitors with the best analyst ratings on the EuroNext exchanges
About DBV.PA
Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
Company Info
DBV TECHNOLOGIES SA
Batiment IRO, 107 Av. de la Republique
Chatillon AUVERGNE-RHONE-ALPES FR
Employees: 110
Phone: 33155427878
DBV TECHNOLOGIES SA / DBV.PA FAQ
What does DBV do?
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Chatillon, Auvergne-Rhone-Alpes and currently employs 109 full-time employees. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.
What is the stock price of DBV TECHNOLOGIES SA today?
The current stock price of DBV.PA is 3.77 EUR. The price increased by 0.13% in the last trading session.
What is the dividend status of DBV TECHNOLOGIES SA?
DBV.PA does not pay a dividend.
What is the ChartMill rating of DBV TECHNOLOGIES SA stock?
DBV.PA has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Where is DBV TECHNOLOGIES SA (DBV.PA) stock traded?
DBV.PA stock is listed on the Euronext Paris exchange.
Can you provide the sector and industry classification for DBV TECHNOLOGIES SA?
DBV TECHNOLOGIES SA (DBV.PA) operates in the Health Care sector and the Biotechnology industry.
How many employees does DBV TECHNOLOGIES SA have?
DBV TECHNOLOGIES SA (DBV.PA) currently has 110 employees.